Ruud Dobber

Executive Vice-President of BioPharmaceuticals Business Unit, AstraZeneca

Search every verified Ruud Dobber interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Ruud Dobber, Executive Vice-President of the BioPharmaceuticals Business Unit at AstraZeneca, spoke at the Politico Healthcare Summit in November 2025, where he argued that Europe is at a "crossroads" regarding medical innovation. Dobber stated that Europe's share of global pharmaceutical R&D has dropped 25% in the past 20 years and that only 40% of new medicines reach Europe compared to 85% in the United States. He said that "falling investments in health and life sciences is threatening to undermine progress" and called for "coordinated action" to ensure Europe remains a center for medical breakthroughs, adding that "health is not only a public good but an economic necessity." During the COVID-19 pandemic, Dobber was a frequent public spokesperson for AstraZeneca's vaccine development and distribution efforts. In 2020 and 2021, he stated the company's goal to supply hundreds of millions of doses globally, including to lower-income countries, and described the vaccine as having a "strong safety profile." He also discussed the company's long-acting antibody cocktail for immunocompromised patients, stating in December 2021 that the company was "hopeful" it would be protective against the Omicron variant. In earlier remarks, Dobber emphasized the company's focus on following the science to address chronic diseases and high unmet medical needs.